Development and Application of Chymase Inhibitors: Therapeutic Potential of a Specific Chymase Inhibitor in Atopic Dermatitis

A novel therapeutic mechanism may be the key to improving the chief symptoms and signs of atopic dermatitis (AD), which are persistent pruritus and high serum IgE. We demonstrate here that mast cell chymase may be a possible initiating factor and that the orally active specific inhibitor Y-40613 may...

Full description

Saved in:
Bibliographic Details
Published inJapanese journal of pharmacology Vol. 90; no. 3; pp. 214 - 217
Main Authors Imada, Teruaki, Komorita, Naruyasu, Kobayashi, Fujio, Naito, Koji, Yoshikawa, Tsutomu, Miyazaki, Mizuo, Nakamura, Norifumi, Kondo, Takao
Format Journal Article
LanguageEnglish
Published The Japanese Pharmacological Society 2002
Subjects
Online AccessGet full text

Cover

Loading…
Abstract A novel therapeutic mechanism may be the key to improving the chief symptoms and signs of atopic dermatitis (AD), which are persistent pruritus and high serum IgE. We demonstrate here that mast cell chymase may be a possible initiating factor and that the orally active specific inhibitor Y-40613 may have a therapeutic potential in the treatment of AD. We found that Y-40613 (2-[5-amino-2-(4-fluorophenyl)-1,6-dihydro-6-oxo-1-pyrimidinyl]-N-{1-[(5-methoxycarbonyl-2-benzoxazolyl)carbonyl]-2-phenylethyl}acetamide) dose-dependently suppressed the scratching response in a mouse pruritus model, with inhibitory efficacy enhanced by combination with conventional drugs, suggesting that chymase contributes to the development of pruritus by a unique mechanism or mechanisms. In fact, chymase injected in the model induced the scratching response. In vitro IgE production from mouse B cells was increased by purified rat chymase and suppressed by Y-40613. Increased serum IgE observed in Brown Norway rats injected with mercury chloride was suppressed by Y-40613. Furthermore, Y-40613 lowered ear thickness as well as serum IgE level in a mouse contact dermatitis model. Taken together, these findings suggest that the specific chymase inhibitor Y-40613 may ameliorate symptoms of AD through the dual inhibition of the chymase-dependent IgE production pathway and itching sensation.
AbstractList A novel therapeutic mechanism may be the key to improving the chief symptoms and signs of atopic dermatitis (AD), which are persistent pruritus and high serum IgE. We demonstrate here that mast cell chymase may be a possible initiating factor and that the orally active specific inhibitor Y-40613 may have a therapeutic potential in the treatment of AD. We found that Y-40613 (2-[5-amino-2-(4-fluorophenyl)-1,6-dihydro-6-oxo-1-pyrimidinyl]-N-{1-[(5-methoxycarbonyl-2-benzoxazolyl)carbonyl]-2-phenylethyl}acetamide) dose-dependently suppressed the scratching response in a mouse pruritus model, with inhibitory efficacy enhanced by combination with conventional drugs, suggesting that chymase contributes to the development of pruritus by a unique mechanism or mechanisms. In fact, chymase injected in the model induced the scratching response. In vitro IgE production from mouse B cells was increased by purified rat chymase and suppressed by Y-40613. Increased serum IgE observed in Brown Norway rats injected with mercury chloride was suppressed by Y-40613. Furthermore, Y-40613 lowered ear thickness as well as serum IgE level in a mouse contact dermatitis model. Taken together, these findings suggest that the specific chymase inhibitor Y-40613 may ameliorate symptoms of AD through the dual inhibition of the chymase-dependent IgE production pathway and itching sensation.
Author Imada, Teruaki
Naito, Koji
Yoshikawa, Tsutomu
Kobayashi, Fujio
Nakamura, Norifumi
Komorita, Naruyasu
Miyazaki, Mizuo
Kondo, Takao
Author_xml – sequence: 1
  givenname: Teruaki
  surname: Imada
  fullname: Imada, Teruaki
  email: Imada.Teruaki@mf.m-pharma.co.jp
  organization: Pharmaceuticals Research Division, Mitsubishi Pharma Corporation, Yokohama 227-0033, Japan
– sequence: 2
  givenname: Naruyasu
  surname: Komorita
  fullname: Komorita, Naruyasu
  organization: Pharmaceuticals Research Division, Mitsubishi Pharma Corporation, Yokohama 227-0033, Japan
– sequence: 3
  givenname: Fujio
  surname: Kobayashi
  fullname: Kobayashi, Fujio
  organization: Pharmaceuticals Research Division, Mitsubishi Pharma Corporation, Yokohama 227-0033, Japan
– sequence: 4
  givenname: Koji
  surname: Naito
  fullname: Naito, Koji
  organization: Pharmaceuticals Research Division, Mitsubishi Pharma Corporation, Yokohama 227-0033, Japan
– sequence: 5
  givenname: Tsutomu
  surname: Yoshikawa
  fullname: Yoshikawa, Tsutomu
  organization: Pharmaceuticals Research Division, Mitsubishi Pharma Corporation, Yokohama 227-0033, Japan
– sequence: 6
  givenname: Mizuo
  surname: Miyazaki
  fullname: Miyazaki, Mizuo
  organization: Depertment of Pharmacology, Osaka Medical College, Osaka 569-8686, Japan
– sequence: 7
  givenname: Norifumi
  surname: Nakamura
  fullname: Nakamura, Norifumi
  organization: Pharmaceuticals Research Division, Mitsubishi Pharma Corporation, Yokohama 227-0033, Japan
– sequence: 8
  givenname: Takao
  surname: Kondo
  fullname: Kondo, Takao
  organization: Pharmaceuticals Research Division, Mitsubishi Pharma Corporation, Yokohama 227-0033, Japan
BookMark eNptkE9LAzEQxYNUsFYvfoKcha1JNtmmXqS0_ikUFOw9pNlZm7JNliQWevC7m1LtRS8TJvN7b5h3iXrOO0DohpIhZYLfbTbdcEyGjPIz1KclHxWlIFUP9QlhtBB0LC_QZYyb3EpCeR99zWAHre-24BLWrsaTrmut0cl6h32Dp-v9VkfAc7e2K5t8iPd4uYagO_hM1uA3n7LS6vYAa_zegbFN_v-jw9bhSfJdns0gbPOCZOMVOm90G-H65x2g5dPjcvpSLF6f59PJojAl5bwoQQhGKmbkakRoTQUpawG0qYwgUpbMmMoAADXVqG6kZtAQVku5kloLxnk5QLdHWxN8jAEa1QW71WGvKFGH3FTOTY2Jyrll-OEIb2LSH3BCdcj3tvCLlseSFaeJWeugwGUHfnSAfNLOQlDRWHAGahvAJFV7-9_ib2ptjW0
CitedBy_id crossref_primary_10_1016_j_jaad_2005_12_001
crossref_primary_10_1111_j_1476_5381_2012_02055_x
crossref_primary_10_1080_13543776_2018_1531848
crossref_primary_10_1177_0022034513488787
crossref_primary_10_1016_j_clindermatol_2018_05_007
crossref_primary_10_1159_000506985
crossref_primary_10_1371_journal_pone_0167964
crossref_primary_10_1111_j_1398_9995_2005_00879_x
crossref_primary_10_1016_j_jaci_2006_03_037
crossref_primary_10_1631_jzus_B1101008
crossref_primary_10_1111_j_1365_2567_2008_02916_x
crossref_primary_10_1111_j_1398_9995_2006_01233_x
crossref_primary_10_1111_j_0906_6705_2005_00321f_x
crossref_primary_10_1111_cea_12259
crossref_primary_10_1186_s12974_020_01795_4
crossref_primary_10_1371_journal_pone_0041107
crossref_primary_10_3390_ijms222212365
crossref_primary_10_1111_j_1365_2222_2004_02000_x
crossref_primary_10_1111_fcp_12275
crossref_primary_10_1007_s10038_005_0252_x
crossref_primary_10_2332_allergolint_R_07_150
Cites_doi 10.1093/intimm/9.3.461
10.1016/0014-2999(94)00780-B
10.2332/allergolint.46.117
10.1159/000022782
10.1159/000236348
10.1159/000045326
10.1046/j.1365-2567.2001.01320.x
10.2340/0001555552125128
10.1046/j.1365-2222.1999.00388.x
10.1016/S0140-6736(95)10244-2
10.1084/jem.160.4.1027
10.1016/S0014-2999(98)00343-4
10.1016/S0021-9258(17)32427-4
10.1159/000022815
ContentType Journal Article
Copyright 2002 Elsevier B.V.
The Japanese Pharmacological Society 2002
Copyright_xml – notice: 2002 Elsevier B.V.
– notice: The Japanese Pharmacological Society 2002
DBID 6I.
AAFTH
AAYXX
CITATION
DOI 10.1254/jjp.90.214
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
DatabaseTitle CrossRef
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1347-3506
EndPage 217
ExternalDocumentID 10_1254_jjp_90_214
article_jjp_90_3_90_3_214_article_char_en
S0021519819300241
GroupedDBID .55
.GJ
123
29J
2WC
3O-
41~
53G
5RE
6I.
AAEDW
AAFTH
AALRI
AAXUO
ACLIJ
ADBBV
AHPSJ
AITUG
AL-
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANFDX
BAWUL
CS3
DIK
E3Z
EBS
F5P
FDB
HH5
JMI
JSF
JSH
KQ8
MOJWN
M~E
NCXOZ
OK1
RJT
RZJ
TKC
TR2
W2D
X7J
X7M
XSB
ZGI
ZXP
08R
AABQG
AAUGY
0SF
AAYXX
ADVLN
AKRWK
CITATION
ID FETCH-LOGICAL-c3144-3e552062c8b701d1503d5e1f6c508832cc6ceee1c67df8a2ef02d88b8aa52443
ISSN 0021-5198
IngestDate Fri Aug 23 00:48:58 EDT 2024
Thu Aug 17 20:28:04 EDT 2023
Fri Feb 23 02:33:55 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Issue 3
Language English
License http://creativecommons.org/licenses/by-nc-nd/4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3144-3e552062c8b701d1503d5e1f6c508832cc6ceee1c67df8a2ef02d88b8aa52443
OpenAccessLink https://dx.doi.org/10.1254/jjp.90.214
PageCount 4
ParticipantIDs crossref_primary_10_1254_jjp_90_214
jstage_primary_article_jjp_90_3_90_3_214_article_char_en
elsevier_sciencedirect_doi_10_1254_jjp_90_214
PublicationCentury 2000
PublicationDate 2002
2002-00-00
PublicationDateYYYYMMDD 2002-01-01
PublicationDate_xml – year: 2002
  text: 2002
PublicationDecade 2000
PublicationTitle Japanese journal of pharmacology
PublicationTitleAlternate Jpn.J.Pharmacol.
PublicationYear 2002
Publisher The Japanese Pharmacological Society
Publisher_xml – name: The Japanese Pharmacological Society
References 4 He S and Walls AF: The induction of a prolonged increase in microvascular permeability by human mast cell chymase. Eur J Pharmacol 352, 91 – 98 (1998)
9 Mao XQ, Shirakawa T, Enomoto T, Shimazu S, Dake Y, Kitano H, Hagihara A and Hopkin JM: Association between variants of mast cell chymase gene and serum IgE levels in eczema. Hum Hered 48, 38 – 41 (1998)
2 Matsuda H, Watanabe N, Geba GP, Sperl J, Tsudzuki M, Hiroi J, Matsumoto M, Ushio H, Saito S, Askenase PW and Ra C: Development of atopic dermatitis-like skin lesion with hyperproduction in NC/Nga mice. Int Immunol 9, 461 – 466 (1997)
10 Tanaka K, Sugiura H, Uehara M, Sato H, Hashimoto-Tamaoki T and Furuyama J: Association between mast cell chymase genotype and atopic eczema: comparison between patients with atopic eczema alone and those with atopic eczema and atopic respiratory disease. Clin Exp Allergy 29, 800 – 803 (1999)
6 Banovac K and De Forteza R: The effect of mast cell chymase on extracellular matrix: Studies in autoimmune thyroiditis and in cultured thyroid cells. Int Arch Allergy Immunol 99, 141 – 149 (1992)
7 Mao XQ, Shirakawa T, Yoshikawa T, Yoshikawa K, Kawai M, Sasaki S, Enomoto T, Hashimoto T, Furuyama J, Hopkin JM and Morimoto K: Association between genetic variants of mast cell chymase and eczema. Lancet 348, 581 – 583 (1996)
8 Kawashima T, Noguchi E, Arinami T, Kobayashi K, Otsuka F and Hamaguchi H: No evidence for an association between a variant of the mast cell chymase gene and atopic dermatitis based on case-control and haplotype-relative-risk analyses. Hum Hered 48, 271 – 274 (1998)
14 Qasim FJ, Mathieson PW, Thiru S and Oliveira DB: Cyclosporin A exacerbates mercuric chloride-induced vasculitis in the Brown Norway rat. Lab Invest 72, 183 – 190 (1995)
15 Nakahama H, Obata K, Sugita M, Horio M, Oka K and Moriyama T: Effect of FK506 in the treatment of autoimmune glomerlonephritis in Brown Norway rats. Nephron 81, 421 – 427 (1999)
1 Redington AE, Polosa R, Walls AF, Howarth PH and Holgate ST: Role of mast cells and basophils in asthma. In Human Basophils and Mast Cells, Vol 62, Clinical Aspects, Edited by Marone G, pp 22 – 59, Karger, Switzerland (1995)
5 Saarinen J, Kalkkinen N, Welgus HG and Kovanen PT: Activation of human interstitial procollagenase through direct cleavage of the Leu-Thr bond by mast cell chymase. J Biol Chem 269, 18134 – 18140 (1994)
16 Yoshikawa T, Imada T, Nakakubo H, Nakamura N and Naito K: Rat mast cell protease-I enhances immunoglobulin E production by mouse B cells stimulated with interleukin-4. Immunology 104, 333 – 340 (2001)
11 Kuraishi Y, Nagasawa T, Hayashi K and Satoh M: Scratching behavior induced by pruritogenic but not algesiogenic agents in mice. Eur J Pharmacol 275, 229 – 233 (1995)
3 Hagermark O, Rajka G and Bergvist U: Experimental itch in human skin elicited by rat mast cell chymase. Acta Dermatol 52, 125 – 128 (1972)
12 Musoh K, Nakamura N, Sakurai T, Inagaki N and Nagai H: Scratching behavior in mice associated with IgE-mediated allergic cutaneous reaction and its pharmacological characterization. Allergol Intern 46, 117 – 124 (1997)
13 Briggaman RA, Schechter NM, Fraki J and Lazarus GS: Degradation of the epidermal-dermal junction by proteolytic enzymes from human skin and human polymorphonuclear leukocytes. J Exp Med 160, 1027 – 1042 (1984)
Redington (10.1254/jjp.90.214_bib1) 1995
Matsuda (10.1254/jjp.90.214_bib2) 1997; 9
Banovac (10.1254/jjp.90.214_bib6) 1992; 99
Kawashima (10.1254/jjp.90.214_bib8) 1998; 48
Mao (10.1254/jjp.90.214_bib9) 1998; 48
Briggaman (10.1254/jjp.90.214_bib13) 1984; 160
Yoshikawa (10.1254/jjp.90.214_bib16) 2001; 104
Tanaka (10.1254/jjp.90.214_bib10) 1999; 29
Mao (10.1254/jjp.90.214_bib7) 1996; 348
Qasim (10.1254/jjp.90.214_bib14) 1995; 72
Nakahama (10.1254/jjp.90.214_bib15) 1999; 81
Kuraishi (10.1254/jjp.90.214_bib11) 1995; 275
Saarinen (10.1254/jjp.90.214_bib5) 1994; 269
Musoh (10.1254/jjp.90.214_bib12) 1997; 46
He (10.1254/jjp.90.214_bib4) 1998; 352
Hagermark (10.1254/jjp.90.214_bib3) 1972; 52
References_xml – volume: 9
  start-page: 461
  year: 1997
  ident: 10.1254/jjp.90.214_bib2
  article-title: Development of atopic dermatitis-like skin lesion with hyper-production in NC /Nga mice
  publication-title: Int Immunol
  doi: 10.1093/intimm/9.3.461
  contributor:
    fullname: Matsuda
– volume: 275
  start-page: 229
  year: 1995
  ident: 10.1254/jjp.90.214_bib11
  article-title: Scratching behavior induced by pruritogenic but not algesiogenic agents in mice
  publication-title: Eur J Pharmacol
  doi: 10.1016/0014-2999(94)00780-B
  contributor:
    fullname: Kuraishi
– volume: 46
  start-page: 117
  year: 1997
  ident: 10.1254/jjp.90.214_bib12
  article-title: Scratching behavior in mice associated with IgE-mediated allergic cutaneous reaction and its pharmacological characterization
  publication-title: Allergol Intern
  doi: 10.2332/allergolint.46.117
  contributor:
    fullname: Musoh
– volume: 48
  start-page: 38
  year: 1998
  ident: 10.1254/jjp.90.214_bib9
  article-title: Association between variants of mast cell chymase gene and serum IgE levels in eczema
  publication-title: Hum Hered
  doi: 10.1159/000022782
  contributor:
    fullname: Mao
– volume: 72
  start-page: 183
  year: 1995
  ident: 10.1254/jjp.90.214_bib14
  article-title: Cyclosporin A exacerbates mercuric chloride-induced vasculitis in the Brown Norway rat
  publication-title: Lab Invest
  contributor:
    fullname: Qasim
– volume: 99
  start-page: 141
  year: 1992
  ident: 10.1254/jjp.90.214_bib6
  article-title: The effect of mast cell chymase on extracellular matrix: Studies in autoimmune thyroiditis and in cultured thyroid cells
  publication-title: Int Arch Allergy Immunol
  doi: 10.1159/000236348
  contributor:
    fullname: Banovac
– volume: 81
  start-page: 421
  year: 1999
  ident: 10.1254/jjp.90.214_bib15
  article-title: Effect of FK506 in the treatment of autoimmune glomerlonephritis in Brown Norway rats
  publication-title: Nephron
  doi: 10.1159/000045326
  contributor:
    fullname: Nakahama
– volume: 104
  start-page: 333
  year: 2001
  ident: 10.1254/jjp.90.214_bib16
  article-title: Rat mast cell protease-I enhances immunoglobulin E production by mouse B cells stimulated with interleukin-4
  publication-title: Immunology
  doi: 10.1046/j.1365-2567.2001.01320.x
  contributor:
    fullname: Yoshikawa
– volume: 52
  start-page: 125
  year: 1972
  ident: 10.1254/jjp.90.214_bib3
  article-title: Experimental itch in human skin elicited by rat mast cell chymase
  publication-title: Acta Dermatol
  doi: 10.2340/0001555552125128
  contributor:
    fullname: Hagermark
– volume: 29
  start-page: 800
  year: 1999
  ident: 10.1254/jjp.90.214_bib10
  article-title: Association between mast cell chymase genotype and atopic eczema: comparison between patients with atopic eczema alone and those with atopic eczema and atopic respiratory disease
  publication-title: Clin Exp Allergy
  doi: 10.1046/j.1365-2222.1999.00388.x
  contributor:
    fullname: Tanaka
– volume: 348
  start-page: 581
  year: 1996
  ident: 10.1254/jjp.90.214_bib7
  article-title: Association between genetic variants of mast cell chymase and eczema
  publication-title: Lancet
  doi: 10.1016/S0140-6736(95)10244-2
  contributor:
    fullname: Mao
– volume: 160
  start-page: 1027
  year: 1984
  ident: 10.1254/jjp.90.214_bib13
  article-title: Degradation of the epidermal-dermal junction by proteolytic enzymes from human skin and human polymorphonuclear leukocytes
  publication-title: J Exp Med
  doi: 10.1084/jem.160.4.1027
  contributor:
    fullname: Briggaman
– volume: 352
  start-page: 91
  year: 1998
  ident: 10.1254/jjp.90.214_bib4
  article-title: The induction of a prolonged increase in microvascular permeability by human mast cell chymase
  publication-title: Eur J Pharmacol
  doi: 10.1016/S0014-2999(98)00343-4
  contributor:
    fullname: He
– start-page: 22
  year: 1995
  ident: 10.1254/jjp.90.214_bib1
  article-title: Role of mast cells and basophils in asthma
  contributor:
    fullname: Redington
– volume: 269
  start-page: 18134
  year: 1994
  ident: 10.1254/jjp.90.214_bib5
  article-title: Activation of human interstitial procollagenase through direct cleavage of the Leu-Thr bond by mast cell chymase
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(17)32427-4
  contributor:
    fullname: Saarinen
– volume: 48
  start-page: 271
  year: 1998
  ident: 10.1254/jjp.90.214_bib8
  article-title: No evidence for an association between a variant of the mast cell chymase gene and atopic dermatitis based on case-control and haplotype-relative-risk analyses
  publication-title: Hum Hered
  doi: 10.1159/000022815
  contributor:
    fullname: Kawashima
SSID ssj0028014
Score 1.3222766
Snippet A novel therapeutic mechanism may be the key to improving the chief symptoms and signs of atopic dermatitis (AD), which are persistent pruritus and high serum...
SourceID crossref
jstage
elsevier
SourceType Aggregation Database
Publisher
StartPage 214
SubjectTerms Atopic dermatitis
Chymase
Inhibitor
Title Development and Application of Chymase Inhibitors: Therapeutic Potential of a Specific Chymase Inhibitor in Atopic Dermatitis
URI https://dx.doi.org/10.1254/jjp.90.214
https://www.jstage.jst.go.jp/article/jjp/90/3/90_3_214/_article/-char/en
Volume 90
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX The Japanese Journal of Pharmacology, 2002, Vol.90(3), pp.214-217
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Ji9swFBZheumldKXTDUHLXGaceh-5t6ELMx1ackhhbkaSJepA4pCxDyn0Z_T_9knPlpVmCtNeRNBim7zP0vee30LIG5WkwlRWDWTCqyBleREUBReBzhRjhZa6kibA-cvX_Pxb-vkqu5pMfnleS10rpvLHjXEl_yNV6AO5mijZf5Csuyh0wG-QL7QgYWhvJWPP48d-BDgbv0ajm8V2CYcU7AHfa1Gbsjq9j8UQcXU8a1rjLYSElGMxeg39eyutWaRt1jD2QSHLra93iC0cuqaYpZ-KYj2mxXaG-4slryxfnatNB-zVbfjNsjF2CtzxN92WY0UWHBN8a4o-WabdLdB1zJqweW3LQB1fNot6x4DhWzONfwhQSOZvx1g9tIddsrO3pt4xHWPI594JAAqvOQEW62kRTt0SP832H8efc0o06hCsLmFtWYRlbMqj34lN_kDDtS8unR5vEu6g5xA-fZ_1Fta-He_7V56zANY_eAxaEjO_T-712gc9Qyg9IBO1ekiOZiin7Qn1sHF9Qo_ozJPgI_LTwxsFvFEPb7TRtEcNHfH2zr8idWgzkzkd0La_jtYrimijI9oek_mnj_P350FfvgPee1DTg0RlWRzmsWTiNIwq0DySKlORzqVRCpJYyhwYmopkflppxmOlw7hiTDDOMyCdyRNysGpW6imhUSFElPIs07JKCx4ynkZKFiJkOs1zzg7J6-G_LteYpKXcl-YhCQYxlD29RNpYAnZunM9QVu6a_Ys-zEmwgaluxIRKws707FYP9JzctbWFrEHvBTloN516CRS3Fa8s4H4DzO2yEA
link.rule.ids 315,783,787,4033,27937,27938,27939
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+and+Application+of+Chymase+Inhibitors%3A+Therapeutic+Potential+of+a+Specific+Chymase+Inhibitor+in+Atopic+Dermatitis&rft.jtitle=Japanese+journal+of+pharmacology&rft.au=Imada%2C+Teruaki&rft.au=Komorita%2C+Naruyasu&rft.au=Kobayashi%2C+Fujio&rft.au=Naito%2C+Koji&rft.date=2002&rft.issn=0021-5198&rft.volume=90&rft.issue=3&rft.spage=214&rft.epage=217&rft_id=info:doi/10.1254%2Fjjp.90.214&rft.externalDBID=n%2Fa&rft.externalDocID=10_1254_jjp_90_214
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-5198&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-5198&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-5198&client=summon